Company KALA BIO, Inc.

KALA

US4831192020

Pharmaceuticals

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-18 pm EDT			5-day change	1st Jan Change
6.81 ^USD	-0.41%		-5.42%	-2.71%

Apr. 02	HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating	MT
Mar. 29	KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of therapies for rare and severe diseases of the eye. The Companyâs biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Companyâs product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived bio factors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its KPI-012 is used for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.

Number of employees: 43

Managers	Title	Age	Since
Mark Iwicki CEO	Chief Executive Officer	57	15-02-28
Mary Reumuth DFI	Director of Finance/CFO	48	14-01-31
Todd Bazemore PSD	President	53	17-11-19
Eric Trachtenberg CMP	Compliance Officer	51	18-04-02
Romulus Brazzell CTO	Chief Tech/Sci/R&D Officer	71	13-01-31
Hannah Deresiewicz IRC	Investor Relations Contact	-	-
Darius Kharabi PRN	Corporate Officer/Principal	45	21-11-14

Members of the board	Title	Age	Since
Andrew Koven BRD	Director/Board Member	66	17-09-27
Gregory Perry BRD	Director/Board Member	63	18-03-04
Howard Rosen BRD	Director/Board Member	66	14-01-05
Charles Myers BRD	Director/Board Member	70	21-10-14
Mark Blumenkranz BRD	Director/Board Member	73	21-11-14
Mark Iwicki CEO	Chief Executive Officer	57	15-02-28
Marjan Farid BRD	Director/Board Member	50	22-10-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	2,816,454	2,311,005 ( 82.05 %)	0	82.05 %
Stock B	0	51,246	0	0

Name	Equities	%	Valuation
Baker Bros. Advisors LP 9.900 %	266,613	9.900 %	2 M $
Lagunita Biosciences LLC 6.255 %	168,454	6.255 %	1 M $
Millennium Management LLC 5.016 %	135,096	5.016 %	1 M $
Millennium Management LLC 4.926 %	132,674	4.926 %	1 M $
Longitude Capital Management Co LLC 4.019 %	108,239	4.019 %	862 665 $
Mary Reumuth 2.456 %	66,136	2.456 %	527 104 $
Vanguard Global Advisers LLC 1.041 %	28,035	1.041 %	223 439 $
BlackRock Institutional Trust Co. NA 1.001 %	26,950	1.001 %	214 792 $
Board of Trustees of the Leland Stanford Junior University 0.7845 %	21,127	0.7845 %	168 382 $
Geode Capital Management LLC 0.6856 %	18,465	0.6856 %	147 166 $

Name	Equities	%	Valuation
Baker Bros. Advisors LP -	1,041	-	8 297 $

KALA BIO, Inc.

1167 Massachusetts Avenue

02476, Arlington

+781 996 5252

http://www.kalarx.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.81 USD

Average target price

19.33 USD

Spread / Average Target

+183.90%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
KALA BIO, INC.	-2.71%	19.26M
ELI LILLY AND COMPANY	+27.97%	676B
NOVO NORDISK A/S	+23.58%	554B
JOHNSON & JOHNSON	-7.02%	349B
MERCK & CO., INC.	+14.85%	318B
ABBVIE INC.	+6.25%	291B
ASTRAZENECA PLC	+2.96%	210B
NOVARTIS AG	-0.41%	204B
ROCHE HOLDING AG	-10.02%	194B
PFIZER, INC.	-11.81%	144B

Other Pharmaceuticals